These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8305226)

  • 1. Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma.
    Lehtinen T; Aine R; Kellokumpu-Lehtinen P; Hakala T; Lehtinen M
    Acta Oncol; 1993; 32(7-8):779-81. PubMed ID: 8305226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
    Møller MB; Nielsen O; Pedersen NT
    Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of germline p53 mutations in familial lymphoma.
    Weintraub M; Lin AY; Franklin J; Tucker MA; Magrath IT; Bhatia KG
    Oncogene; 1996 Feb; 12(3):687-91. PubMed ID: 8637726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between mutations in p53 gene and protein expression in human lymphomas.
    Martinez-Delgado B; Robledo M; Arranz E; Infantes F; Echezarreta G; Marcos B; Sanz C; Rivas C; Benitez J
    Am J Hematol; 1997 May; 55(1):1-8. PubMed ID: 9136910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas.
    Doglioni C; Pelosio P; Mombello A; Scarpa A; Chilosi M
    Hematol Pathol; 1991; 5(2):67-73. PubMed ID: 1680118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma.
    Nieder C; Petersen S; Petersen C; Thames HD
    Ann Hematol; 2001 Jan; 80(1):2-8. PubMed ID: 11233771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [p53 mutation does not determine prognosis in non-Hodgkin's lymphoma].
    Osada M; Ishioka C; Murakawa Y; Ichinohasama R; Kanamaru R; Ikawa S
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):471-5. PubMed ID: 9063486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
    Jezersek B; Rudolf Z; Novakovic S
    Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53 gene mutations in non-Hodgkin's lymphoma.
    Chen Y; Xiang Z; Li H; Yang N; Zhang H
    J Tongji Med Univ; 1999; 19(1):27-30. PubMed ID: 12840870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma.
    Osada M; Ishioka C; Ichinohasama R; Kadowaki I; Murakawa Y; Watanabe M; Kanamaru R; Ikawa S
    Anticancer Drug Des; 1999 Apr; 14(2):107-14. PubMed ID: 10405637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.
    Ellims PH; Eng Gan T; Medley G; Van Der Weyden MB
    Blood; 1981 Nov; 58(5):926-30. PubMed ID: 7296003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.
    Carbone A; Dolcetti R; Gloghini A; Maestro R; Vaccher E; di Luca D; Tirelli U; Boiocchi M
    Hum Pathol; 1996 Feb; 27(2):133-46. PubMed ID: 8617454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
    Lehtinen T
    Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.
    Korkolopoulou P; Oates J; Kittas C; Crocker J
    J Clin Pathol; 1994 Jan; 47(1):9-14. PubMed ID: 7907610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in-house assay for serum deoxythymidine kinase.
    Seah LH; Ton SH; Cheong SK; Hamidah NH
    Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutation and expression in lymphoma.
    Adamson DJ; Thompson WD; Dawson AA; Bennett B; Haites NE
    Br J Cancer; 1995 Jul; 72(1):150-4. PubMed ID: 7599045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 as a marker of the malignant cell in Hodgkin's disease.
    Pasman PC; Tiebosch A; Erdkamp FL; Vrints LW; Breed WP; Schouten HC
    Ann Oncol; 1994; 5 Suppl 1():89-91. PubMed ID: 8172826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
    Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
    Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
    Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
    Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.